Anixa Biosciences, Inc., k'hamphani ea biotechnology e shebaneng le kalafo le thibelo ea mofets'e le mafu a tšoaetsanoang, kajeno e phatlalalitse hore Ofisi ea Patent ea Japane e fane ka Qeto ea ho fana ka tumello ho Cleveland Clinic e bitsitsoeng, "Liente tsa Kankere ea Ovarian." Theknoloji ena e ile ea qaptjoa ke Dr. Vincent K. Tuohy, Suparna Mazumder le Justin M. Johnson ho Cleveland Clinic. Anixa ke mong'a laesense ea lefats'e bakeng sa theknoloji ea ente. Litokelo tsa theknoloji li ile tsa fanoa US le Europe ka 2021.

eTurboNews lingoliloeng ke tsa ba ngolisitseng feela. Ngoliso ke FREE.
Ba ngolisitseng ba kena mona Tobetsa mona ho ingolisa MAHALA

SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:

, a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the Japanese Patent Office has issued a Decision to Grant of a patent to Cleveland Clinic titled, “Ovarian Cancer Vaccines.
Patents for the technology were issued in the U.
Anixa is the worldwide licensee for the vaccine technology.